Plitidepsin
Plitidepsin is a chemotherapy derived from a Mediterranean sea squirt, approved in Australia in 2018 with dexamethasone for multiple myeloma after several other treatments; the European regulator refused it, and it drew attention in 2021 as a possible COVID-19 antiviral.
Overview
PharmaMar isolated plitidepsin from the tunicate Aplidium albicans. In the phase 3 ADMYRE trial in relapsed and refractory multiple myeloma, plitidepsin with dexamethasone improved progression-free survival over dexamethasone alone by about a month, and the Therapeutic Goods Administration approved it in Australia in December 2018 for patients who had received at least three prior regimens including a proteasome inhibitor and an immunomodulator. The European Medicines Agency refused marketing authorisation in 2018, judging the benefit too small against the toxicity, and the FDA never approved it. Its inhibition of eEF1A2 also blocks SARS-CoV-2 replication in cells, which led to COVID-19 trials.
Binds the translation elongation factor eEF1A2, triggering oxidative stress and rapid apoptosis in myeloma cells. Connects to Elongation factor 2 (EEF2).
1.Plitidepsin slips into a pocket on Elongation factor 2 (EEF2).
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Plitidepsin" OR ABSTRACT:"Plitidepsin" OR TITLE:"Aplidin" OR ABSTRACT:"Aplidin" OR TITLE:"Dehydrodidemnin B" OR ABSTRACT:"Dehydrodidemnin B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Plitidepsin, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentAltretamine
Shares Cytotoxic chemotherapy and the tag chembl-universe.
- TreatmentAlitretinoin
Shares Cytotoxic chemotherapy and the tag chembl-universe.
- TreatmentPorfimer sodium
Shares Cytotoxic chemotherapy and the tag chembl-universe.
- TreatmentPlicamycin
Shares Cytotoxic chemotherapy and the tag chembl-universe.
- TreatmentUracil mustard
Shares Cytotoxic chemotherapy and the tag chembl-universe.
- TreatmentEstramustine
Shares Cytotoxic chemotherapy and the tag chembl-universe.
- TreatmentFloxuridine
Shares Cytotoxic chemotherapy and the tag chembl-universe.
- TreatmentTeniposide
Shares Cytotoxic chemotherapy and the tag chembl-universe.